European Radiology

, Volume 20, Issue 1, pp 48–55 | Cite as

Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI

  • Olivier Rouvière
  • Nicolas Girouin
  • Ludivine Glas
  • Alexandre Ben Cheikh
  • Albert Gelet
  • Florence Mège-Lechevallier
  • Muriel Rabilloud
  • Jean-Yves Chapelon
  • Denis Lyonnet


The objective was to evaluate T2-weighted (T2w) and dynamic contrast-enhanced (DCE) MRI in detecting local cancer recurrences after prostate high-intensity focused ultrasound (HIFU) ablation. Fifty-nine patients with biochemical recurrence after prostate HIFU ablation underwent T2-weighted and DCE MRI before transrectal biopsy. For each patient, biopsies were performed by two operators: operator 1 (blinded to MR results) performed random and colour Doppler-guided biopsies (“routine biopsies”); operator 2 obtained up to three cores per suspicious lesion on MRI (“targeted biopsies”). Seventy-seven suspicious lesions were detected on DCE images (n = 52), T2w images (n = 2) or both (n = 23). Forty patients and 41 MR lesions were positive at biopsy. Of the 36 remaining MR lesions, 20 contained viable benign glands. Targeted biopsy detected more cancers than routine biopsy (36 versus 27 patients, p = 0.0523). The mean percentages of positive cores per patient and of tumour invasion of the cores were significantly higher for targeted biopsies (p < 0.0001). The odds ratios of the probability of finding viable cancer and viable prostate tissue (benign or malignant) at targeted versus routine biopsy were respectively 3.35 (95% CI 3.05–3.64) and 1.38 (95% CI 1.13–1.63). MRI combining T2-weighted and DCE images is a promising method for guiding post-HIFU biopsy towards areas containing recurrent cancer and viable prostate tissue.


Prostate cancer MRI Dynamic-contrast enhanced MRI Biochemical recurrence HIFU 


  1. 1.
    Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D, Blanc E (1993) Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol 7:249–253CrossRefPubMedGoogle Scholar
  2. 2.
    Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, Bouvier R (1993) High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol 23 Suppl 1:44–47Google Scholar
  3. 3.
    Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A (1992) In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 52:6353–6357PubMedGoogle Scholar
  4. 4.
    Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51:381–387CrossRefPubMedGoogle Scholar
  5. 5.
    Chaussy C, Thuroff S, Rebillard X, Gelet A (2005) Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2:191–198CrossRefPubMedGoogle Scholar
  6. 6.
    Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY,Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55:640–647. doi:10.1016/j.eururo.2008.04.091 Google Scholar
  7. 7.
    Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, Janier M, Vallancien G (2004) Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63:625–629CrossRefPubMedGoogle Scholar
  8. 8.
    Blana A, Walter B, Rogenhofer S, Wieland WF (2004) High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63:297–300CrossRefPubMedGoogle Scholar
  9. 9.
    Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, Satoh T (2006) Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13:228–233CrossRefPubMedGoogle Scholar
  10. 10.
    Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24:585–590CrossRefPubMedGoogle Scholar
  11. 11.
    Pasticier G, Chapet O, Badet L, Ardiet JM, Poissonnier L, Murat FJ, Martin X, Gelet A (2008) Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 72:1305–1309CrossRefPubMedGoogle Scholar
  12. 12.
    Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D (2007) Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol 63:317–327CrossRefPubMedGoogle Scholar
  13. 13.
    Rouviere O, Mege-Lechevallier F, Chapelon JY, Gelet A, Bouvier R, Boutitie F, Lyonnet D (2006) Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 50:490–497CrossRefPubMedGoogle Scholar
  14. 14.
    Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM, Colombel M, Lyonnet D, Rouviere O (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17:1498–1509CrossRefPubMedGoogle Scholar
  15. 15.
    Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS (2005) Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 22:639–646CrossRefPubMedGoogle Scholar
  16. 16.
    Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432–2437CrossRefPubMedGoogle Scholar
  17. 17.
    Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458CrossRefPubMedGoogle Scholar
  18. 18.
    Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, Gelet A, Lyonnet D (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor—correlation with biopsy findings. Urology 63:922–927CrossRefPubMedGoogle Scholar
  19. 19.
    Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430PubMedGoogle Scholar
  20. 20.
    Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, Gualdi GF (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190:1187–1192CrossRefPubMedGoogle Scholar
  21. 21.
    Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769CrossRefPubMedGoogle Scholar
  22. 22.
    Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C (2008) MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 246:833–844CrossRefPubMedGoogle Scholar
  23. 23.
    Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40:265–274CrossRefPubMedGoogle Scholar
  24. 24.
    Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mege-Lechevallier F, Gelet A, Chapelon JY, Lyonnet D, Rouviere O (2008) MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol 89:571–577CrossRefPubMedGoogle Scholar
  25. 25.
    Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190:1180–1186CrossRefPubMedGoogle Scholar
  26. 26.
    Rouviere O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Marechal JM, Lyonnet D (2003) Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13:931–942PubMedGoogle Scholar
  27. 27.
    Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M 3rd, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448CrossRefPubMedGoogle Scholar
  28. 28.
    Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M 3rd (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055CrossRefPubMedGoogle Scholar
  29. 29.
    Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553CrossRefPubMedGoogle Scholar
  30. 30.
    Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR (1996) Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48:594–599CrossRefPubMedGoogle Scholar
  31. 31.
    Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600CrossRefPubMedGoogle Scholar
  32. 32.
    Casciani E, Bertini L, Gualdi G (2008) Re: Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. doi:10.1016/j.eururo.2008.06.029
  33. 33.
    Lim HK, Kim JK, Kim KA, Cho KS (2009) Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection—a multireader study. Radiology 250:145–151CrossRefPubMedGoogle Scholar
  34. 34.
    Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA (2008) Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging—correlation with pathologic findings. Radiology 246:480–488CrossRefPubMedGoogle Scholar
  35. 35.
    Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M (2008) Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 49:1207–1213CrossRefPubMedGoogle Scholar
  36. 36.
    Futterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, Witjes JA, Barentsz JO (2007) Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 17:1055–1065CrossRefPubMedGoogle Scholar
  37. 37.
    Ben Cheikh A, Girouin N, Colombel M, Marechal JM, Gelet A, Bissery A, Rabilloud M, Lyonnet D, Rouviere O (2009) Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19:770–778CrossRefPubMedGoogle Scholar
  38. 38.
    Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, Gelet A, Murat FJ, Rebillard X, Robertson S, Thuroff S, Ward JF,Rewcastle JC (2009) Defining biochemical failure following high intensity focused ultrasound of the prostate: the Stuttgart definition, presented at the 24th annual EAU congress, StockholmGoogle Scholar
  39. 39.
    Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedGoogle Scholar

Copyright information

© European Society of Radiology 2009

Authors and Affiliations

  • Olivier Rouvière
    • 1
    • 2
    • 3
    • 8
  • Nicolas Girouin
    • 1
    • 2
    • 3
  • Ludivine Glas
    • 1
    • 2
    • 3
  • Alexandre Ben Cheikh
    • 1
    • 2
    • 3
  • Albert Gelet
    • 4
    • 8
  • Florence Mège-Lechevallier
    • 5
  • Muriel Rabilloud
    • 6
    • 7
  • Jean-Yves Chapelon
    • 8
  • Denis Lyonnet
    • 1
    • 2
    • 3
    • 8
  1. 1.Hospices Civils de Lyon, Department of Urinary and Vascular RadiologyHôpital Edouard HerriotLyonFrance
  2. 2.Université de LyonLyonFrance
  3. 3.Faculté de médecine Lyon NordUniversité de Lyon 1LyonFrance
  4. 4.Hospices Civils de Lyon, Department of UrologyHôpital Edouard HerriotLyonFrance
  5. 5.Hospices Civils de Lyon, Department of PathologyHôpital Edouard HerriotLyonFrance
  6. 6.Hospices Civils de Lyon, Department of BiostatisticsLyonFrance
  7. 7.Université de Lyon 1, UMR CNRS 5558, Laboratoire Biostatistiques-SantéPierre-BéniteFrance
  8. 8.Inserm, U556LyonFrance

Personalised recommendations